IMPLANTICA SDR Aktie

 

VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop® - Strategic Preparation Sets the Stage for Success Significant events in the second quarter of 2026 RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued......

VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- FDA Approval of RefluxStop® - Strategic Preparation Sets the Stage for Success Significant events in the second quarter of 2026 RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued......

FDA Approval of RefluxStop® – Strategic Preparation Sets the Stage for Success Significant events in the second quarter of 2026 · RefluxStop® sales increased by more than 60% compared with the prior-year period, reflecting continued commercial growth across key European markets · Largest independent RefluxStop® study to date published in Nature's Scientific Reports, reporting mid- to long-term safety outcomes in 602 patients across 22 centers in six European countries, with serious safety events and reoperations below 2% · Clinical, health-economic and reimbursement evidence...

VADUZ, Liechtenstein, Aug. 21, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announced today that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for RefluxStop®, the......

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announced today that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for RefluxStop®, the company's implant-based treatment for gastroesophageal reflux disease (GERD). The approval allows Implantica to begin commercial launch activities in the United States, the world's largest medical device market. FDA approval represents a transformational milestone for Implantica and follows the FDA's full review of the RefluxStop® PMA application, including the...

VADUZ, Liechtenstein, Aug. 14, 2026 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the second quarter 2026 at 15:00 CEST on August 21. The interim report for the second quarter (Q2 2026) will be published at 8:00 a.m. CEST on the same day. The presentation......

VADUZ, Liechtenstein, June 10, 2026 /PRNewswire/ -- Today, June 10, 2026, the annual general meeting (the "AGM") of Implantica AG (publ) was held in Ruggell, Liechtenstein. The general meeting resolved to adopt all of the board of directors' resolution proposals. A summary of the......

VADUZ, Liechtenstein, June 9, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers,......

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, establishes a new RefluxStop® Center of Excellence in Spain, MD Anderson Cancer Center Madrid-Hospiten, part of the world-renowned U.S. hospital group MD Anderson Cancer group. The RefluxStop® procedure was performed by Oscar Alonso MD, PhD, GI Surgical Oncologist and Head of Robotic Gastrointestinal Surgery at MD Anderson Cancer Center Madrid-Hospiten, marking the...

VADUZ, Liechtenstein, May 22, 2026 /PRNewswire/ -- Substantially Advancing Clinical Outcomes & Economic Impact of RefluxStop® Significant events in the first quarter of 2026 Secured over EUR 1.2 million in new multi-year public tender approvals in Italy, further strengthening......

Substantially Advancing Clinical Outcomes & Economic Impact of RefluxStop® Significant events in the first quarter of 2026 · Secured over EUR 1.2 million in new multi-year public tender approvals in Italy, further strengthening RefluxStop®'s commercial adoption and reimbursement position within the Italian national healthcare system · Expanded the RefluxStop® Centers of Excellence network in Germany with the addition of Klinikum St. Georg in Leipzig and St. Vincenz Hospital Menden, both InEK reporting hospitals supporting Implantica's reimbursement strategy through the InEK DRG...

VADUZ, Liechtenstein, May 21, 2026 /PRNewswire/ -- The depository receipt holders of Implantica AG, reg. no. FL-0002.629.889-3, are hereby invited to attend the annual general meeting to be held on Wednesday, June 10, 2026, at 14:00 at Hotel Kommod, Industriering 14, 9491 Ruggell,......

VADUZ, Liechtenstein, May 21, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces a......

VADUZ, Liechtenstein, May 20, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers,......

VADUZ, Liechtenstein, May 19, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers,......

VADUZ, Liechtenstein, May 19, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers,......

VADUZ, Liechtenstein, May 18, 2026 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the first quarter 2026 at 15:00 CET on May 22. The interim report for the first quarter (Q1 2026) will be published at 8:00 a.m. CET on the same day. The presentation will be in......

VADUZ, Liechtenstein, May 6, 2026 /PRNewswire/ -- Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2025. The annual report is now available on the company's website. "Implantica is......

Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2025. The annual report is now available on the company's website. “Implantica is approaching a potentially defining moment with the FDA PMA process, while at the same time standing on a firm foundation of long-term clinical evidence, real-world validation, cost-effectiveness support, and operational launch readiness. Our priority remains clear: to execute a successful U.S. launch, pending FDA approval, while continuing to scale...

VADUZ, Liechtenstein, April 21, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux - a condition affecting over 1 billion people......